Clozapine tablets are an atypical antipsychotic indicated for: Treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, clozapine tablets should be used only in patients who have failed to respond adequately to standard antipsychotic treatment. Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior. 1.
| Apr 15, 2010 | Supplement 24Efficacy (new indication or use) | Approved | |
| Apr 15, 2010 | Supplement 21Efficacy (new indication or use) | Approved | |
| May 27, 1999 | Original application | Approved |
| Oct 2, 2026 | Supplement 64Labeling · Standard review | Approved | None posted |
| Oct 2, 2026 | Supplement 62Labeling · Standard review | Approved | None posted |
| Oct 2, 2026 | Supplement 61Labeling · Standard review | Approved | None posted |
| Jun 13, 2025 | Supplement 63REMS | Approved | None posted |
| Jul 8, 2024 | Supplement 59Labeling · Standard review | Approved | None posted |
| Jul 8, 2024 | Supplement 57Labeling · Standard review | Approved | None posted |
| Jul 8, 2024 | Supplement 47Labeling · Standard review | Approved | None posted |
| Jul 8, 2024 | Supplement 44Labeling · Standard review | Approved | None posted |
| Nov 10, 2021 | Supplement 51REMS | Approved | None posted |
| Jul 29, 2021 | Supplement 49REMS | Approved | None posted |
| Feb 18, 2021 | Supplement 46REMS | Approved | None posted |
| Jan 16, 2019 | Supplement 41REMS | Approved | None posted |
| Apr 25, 2017 | Supplement 40Labeling · Standard review | Approved | None posted |
| Apr 25, 2017 | Supplement 39Labeling · Standard review | Approved | None posted |
| Apr 25, 2017 | Supplement 38Labeling · Standard review | Approved | None posted |
| Sep 15, 2015 | Supplement 37REMS | Approved | None posted |
| Sep 14, 2015 | Supplement 36Labeling · Standard review | Approved | None posted |
| Dec 13, 2014 | Supplement 35Labeling · Standard review | Approved | None posted |
| Dec 13, 2014 | Supplement 34Labeling · Standard review | Approved | None posted |
| Aug 26, 2013 | Supplement 33Labeling · Standard review | Approved | None posted |
| May 20, 2013 | Supplement 31Labeling | Approved | None posted |
| Apr 11, 2011 | Supplement 30Labeling | Approved | None posted |
| Apr 30, 2010 | Supplement 28Labeling | Approved | None posted |
| Apr 15, 2010 | Supplement 25Labeling | Approved | |
| Apr 15, 2010 | Supplement 24Efficacy (new indication or use) | Approved | |
| Apr 15, 2010 | Supplement 21Efficacy (new indication or use) | Approved | |
| Apr 8, 2009 | Supplement 22Labeling | Approved | None posted |
| Nov 19, 2008 | Supplement 18Labeling | Approved | None posted |
| Oct 31, 2006 | Supplement 11Labeling | Approved | None posted |
| Oct 13, 2006 | Supplement 10Labeling | Approved | None posted |
| Apr 8, 2005 | Supplement 9Labeling | Approved | None posted |
| Mar 31, 2003 | Supplement 6Labeling | Approved | None posted |
| Mar 17, 2003 | Supplement 4Labeling | Approved | None posted |
| Mar 12, 2001 | Supplement 1Labeling | Approved | None posted |
| May 27, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters